Saraf and Partners advises an array of global pharma clients including Mylan and Viatris on regulatory issues relating to marketing approvals, drug manufacturing, and distribution, as well as private equity deals and M&A, including distressed acquisitions and restructurings. The team also has expertise in tech, allowing it to advise a range of medtech and medical devices companies, as well as on investments in these sectors. Mohit Saraf and Vaibhav Kakkar , who are both experienced transactional advisers with notable healthcare and life sciences regulatory experience, head up the team, with Vikrant Kumar also a key name for tech and product licensing. All lawyers named are based in New Delhi.

Legal 500 Editorial commentary

Key clients

  • Fortis Healthcare
  • Viatris Inc./ Mylan Inc. (Viatris)
  • Vedanta Group
  • Takeda Pharmaceuticals India Private Limited
  • Carlyle Group

Work highlights

  • Advised Viatris on the sale of its global biosimilars assets to Biocon Biologics Limited.

Practice head

The lawyer(s) leading their teams.

Mohit Saraf, Vaibhav Kakkar

Other key lawyers

Vikrant Kumar